Composition and methods to improve neural outcome
CA 2178711 A1 · Owner: Auckland Uniservices Limited · Inventors: Gluckman, Peter David; Williams, Christopher Edward
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The tripeptide glycine-proline-glutamine(GPE) may be administered before or usually after injury to reduce damage to the central, nervous system. GPE appears useful for neuronal rescue particularly but not exclusively within the hippocampus. Advantages of GPE include a) that it crosses the blood-brain barrier so is effective by injected peripheral administration; b) it is unlikely to challenge the immune system; c) it is cheap: and d) its therapeutic ratio is high. GPE may be also be infused into the CSF. It may be administered prior to parturition or elective brain or cardiac surgery. Transdermal routes may be useful for chronic neural disorders. The CNS of mammals (including foetal …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 20, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 20, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 20, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.